Company: SUPN
Filing Date: 2025-07-31
Form Type: 8-K
Source: 0001104659-25-072506
Chunk: 1

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-07-31
Form: 8-K
Item: Item 2.01
Chunk 1
---
Item 2.01      Completion of Acquisition or Disposition of Assets.  

Pursuant to the Merger Agreement,
on July 2, 2025, Purchaser commenced a tender offer to purchase all of the outstanding shares of common stock of Sage, par value
$0.0001 per share (the “ Shares”), at a price of (i) $8.50 per Share, in cash, less any applicable withholding
taxes and without interest (the “ Closing Amount”), plus (ii) one contingent value right per Share (a “CVR”),
which represents the right to receive contingent payments of up to $3.50 per Share, in cash, less any applicable withholding taxes and
without interest, which amount will become payable, if at all, if specified milestones are achieved prior to June 30, 2026, December 31,
2027, December 31, 2028 and December 31, 2030, as applicable, pursuant to the CVR Agreement (collectively, the Closing Amount
plus one CVR, the “ Offer Price”), upon the terms and subject to the conditions set forth in the Offer to Purchase,
dated July 2, 2025 (together with any amendments, supplements or modifications thereto, the “ Offer to Purchase”),
and in the related Letter of Transmittal (together with any amendments, supplements, or modifications thereto, the “ Letter of
Transmittal” and, together with the Offer to Purchase, the “ Offer”).